| V |
|
VALIDATION OF AN IMPROVED PRION AND VIRUS ELIMINATION PROCESS IN THE MANUFACTURE OF BOVINE THROMBIN, A TOPICAL HEMOSTAT USED IN SURGERY
|
| Terrab A., Pawlak D. |
| |
|
VALIDATION OF THE PROTEIN C/S RATIO TO IDENTIFY CARRIERS OF A PROTEIN S GENE MUTATION
|
| ten Kate M.K., Mulder R., Platteel M., Mulder A.B., van der Steege G., van der Meer J. |
| |
|
VARIABILITY IN ANTICOAGULANT DOSING RECOMMENDATIONS; RESULTS FROM TWO UK NEQAS FOR BLOOD COAGULATION EXERCISES
|
| Jennings I., Kitchen D.P., Kitchen S., Woods T.A.L., Walker I.D. |
| |
|
VARIABILITY IN PERFORMING PLATELET AGGREGOMETRY FOR DIAGNOSIS OF INBORN DISORDERS OF PLATELET FUNCTION IN GERMANY, AUSTRIA AND SWITZERLAND
|
| Olivieri M., Knöfler R., Weickardt S., Eberl W., Streif W. |
| |
|
VARIATIONS IN PLATELET FUNCTION TEST OF NORMAL INDIVIDUALS MAY AFFECT TEST INTERPRETATIONS
|
| Refaai M., Kim A., Sarode R. |
| |
|
VARIATIONS OF PLATELET GLYCOPROTEIN IIB-IIIA QUANTITY AFFECTS PLATELET AGGREGATION AND SENSITIVITY TO GLYCOPROTEIN IIB-IIIA ANTAGONISTS
|
| Mazurov A.V., Khaspekova S.G., Zabotina A.M., Shimanova Y.V., Sirotkina O.V. |
| |
|
VARIEGIN, A NOVEL CLASS OF THROMBIN INHIBITOR FROM THE SALIVARY GLAND EXTRACT OF THE HARD TICK AMBLYOMMA VARIEGATUM
|
| Koh C.Y., Kazimirova M., Trimnell A., Takac P., Labuda M., Nuttall P., Kini R.M. |
| |
|
VASCULAR BED-SPECIFIC THROMBOSIS
|
| Aird W. |
| |
|
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN TRANSFUSION-DEPENDENT THALASSEMIC PATIENTS: RELATION TO BLOOD TRANSFUSION
|
| Jang R.C., Chiou S.S., Lin P.C., Chang T.T., Lin K.S. |
| |
|
VASCULAR PROTEOMIC MAPPING IN VIVO
|
| Simonson A.B., Schnitzer J.E. |
| |
|
VASCULAR WALL ALTERATIONS AND MATRIX EXPOSURE FOLLOWING LASER-INDUCED INJURY OF MOUSE MESENTERIC ARTERIOLES
|
| Nonne C., Eckly A., Hechler B., Cazenave J.P., Lanza F., Gachet C. |
| |
|
VASP PHOSPHORYLATION ANALYSIS PRIOR TO PERCUTANEOUS CORONARY INTERVENTION FOR EXCLUSION OF POST-PROCEDURAL MAJOR ADVERSE CARDIOVASCULAR EVENTS
|
| Camoin-Jau L., Bonello L., Paganelli F., Arpin M., Sampol J., Dignat-George F., Barragan P. |
| |
|
VEGF FUNCTION FOR UPREGULATION OF ENDOGENOUS PLGF EXPRESSION DURING FGF-2-MEDIATED THERAPEUTIC ANGIOGENESIS
|
| Fujii T., Yonemitsu Y., Onimaru M., Sueishi K. |
| |
|
VEGF-C PROMOTE OF THE GROWTH AND ANGIOGENESIS IN NB4 CELL XENOGRAFT TUMOR
|
| Ding K., Bai X., Dong N., Ruan C. |
| |
|
VENOUS FUNCTION AND CLINICAL OUTCOME FOLLOWING DEEP VEIN THROMBOSIS
|
| Jalali F. |
| |
|
VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS UNDERGOING CHEST SURGERY FOR LUNG OR PLEURAL MALIGNANT DISEASE
|
| Dentali F., Malato A., Douketis J., Crowther M. |
| |
|
VENOUS THROMBOEMBOLISM AND ATHEROSCLEROSIS: IS THERE A LINK?
|
| Prandoni P. |
| |
|
VENOUS THROMBOEMBOLISM AND CANCER: THE PERCEIVE REGISTRY
|
| Petralia G.A., Rickard M., Baginski M., Saba N., Wong J., Pabinger I., Young A., Kakkar A.K. |
| |
|
VENOUS THROMBOEMBOLISM AND GYNAECOLOGICAL ONCOLOGY SURGERY
|
| Fletcher J.P., Hitos K., Wain G. |
| |
|
VENOUS THROMBOEMBOLISM AND SUBSEQUENT HOSPITALIZATION DUE TO ACUTE CARDIOVASCULAR EVENTS. A 20 YEARS FOLLOW-UP STUDY
|
| Sorensen H.T., Horvath-Puho E., Pedersen L., Baron J.A., Prandoni P. |
| |
|
VENOUS THROMBOEMBOLISM ASSOCIATED POLYMORPHISMS IN SLOVENE POPULATION
|
| Bedencic M., Bo[zcaron]i[ccaron] M., Stegnar M. |
| |
|
VENOUS THROMBOEMBOLISM IN ACUTE LEUKEMIA PATIENTS: INCIDENCE, RISK FACTORS, AND MORTALITY
|
| Wun T., Ku G., Chew H., Zhou H., Harvey D., White R. |
| |
|
VENOUS THROMBOEMBOLISM IN CHINA: A SINGLE-CENTER EXPERIENCE FOR 11 YEARS
|
| Zhao Y., Wang S., Yan Z., Hua B., Fan L., Zhu T., Bai C., Pan J. |
| |
|
VENOUS THROMBOEMBOLISM IN YOUNG PATIENTS: ROLE OF GENETIC POLYMORPHISMS IN SELECTINS AND TISSUE FACTOR
|
| Tassies D., Monteagudo J., Freire C., Pijoan J., Corbella M., Reverter J.C. |
| |
|
VENOUS THROMBOEMBOLISM PROPHYLAXIS IN CRITICALLY-ILL SURGICAL PATIENTS
|
| Masaun R., Hitos K., Fletcher J.P. |
| |
|
VENOUS THROMBOEMBOLISM, FACTOR V LEIDEN, AND PROTHROMBIN 20210 AMONG AMERICAN CAUCASIANS IN THE GATE STUDY
|
| Austin H., Lally C., Benson J., Dowling N., Hooper C. |
| |
|
VENOUS THROMBOSIS (VTE) HAS AN ADVERSE IMPACT ON THE SURVIVAL IN PATIENTS WITH MALIGNANCY
|
| Paneesha S., Lokare A., Lester Z., Nokes T., Arya R., Farren T., McManus A., Pressley F., Scriven N., O'Shaughnessy D., Rose P. |
| |
|
VENOUS THROMBOSIS AND THE POST THROMBOTIC SYNDROME AFTER FEMORAL CATHETERIZATION
|
| Sol J.J., Knoester H., Peters M., van Ommen H. |
| |
|
VENOUS THROMBOSIS DURING ORAL CONTRACEPTION IN NORMAL OR THROMBOPHILIC WOMEN WHO HAD REMAINED ASYMPTOMATIC DURING PAST PREGNANCIES
|
| Girolami A., Scandellari R., Spiezia L., Allemand E., Girolami B. |
| |
|
VENOUS THROMBOSIS IN THE ELDERLY
|
| Rosendaal F.F., van Hylckama Vlieg A., Doggen C.J.M. |
| |
|
VENOUS THROMBOSIS IN UNUSUAL SITES: A SINGLE INSTITUTION EXPERIENCE
|
| Iannaccaro P., Santoro R., Muleo G. |
| |
|
VERY LOW FREQUENCY OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN A TERTIARY CARE HOSPITAL
|
| Wells P.S., Forster A., Lee J., Langlois N., Martel N. |
| |
|
VICENZA MUTATION R1205H IDENTIFIED IN TWO TYPE 1 VON WILLEBRAND DISEASE FAMILIES FROM ISRAEL
|
| Hashemi soteh M.B., Inbal A., Anson J., Peake I., Goodeve A. |
| |
|
VIRAL MYOCARDITIS IS A HYPERCOAGULATIVE STATE. INCREASED TISSUE FACTOR EXPRESSION AND PLASMA THROMBOGENICITY
|
| Antoniak S., Boltzen U., Kallwellis-Opara A., Bobbert P., Riad A., Poller W., Pauschinger M., Schultheiss H., Rauch U. |
| |
|
VISUAL APPROACH TO PROTEOMICS
|
| Baumeister W. |
| |
|
VISUALIZATION OF THROMBUS FORMATION ON ACUTELY RUPTURED PLAQUES IN VIVO
|
| Kuijpers M.J.E., Gilio K., Megens R.T.A., Lutgens E., Heeneman S., van Zandvoort M.A.M.J., oude Egbrink M.G.A., Heemskerk J.W.M. |
| |
|
VITAMIN B6 AND FOLIC ACID ARE RISK FACTORS FOR RETINAL VEIN OCCLUSION INDEPENDENTLY OF HOMOCYSTEINE LEVELS
|
| Bolli P., Sofi F., Marcucci R., Fedi S., Giambene B., Sodi A., Menchini U., Abbate R., Gensini G., Prisco D. |
| |
|
VITAMIN E SUPPRESSES THROMBIN GENERATION INDUCED BY SYSTEMIC HYPOXIA
|
| Wang J.S. |
| |
|
VITAMIN K DEFICIENCY IN PATIENTS WITH CANCER REFERRED TO A HOSPITAL PALLIATIVE CARE TEAM
|
| Harrington D.J., Seton-Jones C., Rangarajan S., Card D.J., Gorska R., Voong K., Shearer M.J., Beynon T., Western H. |
| |
|
VITAMIN K-INDUCED VARIATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY
|
| Marchetti G., Lunghi B., Lapecorella M., Canella A., Sbrighi S., Caruso P., Mariani G., Bernardi F. |
| |
|
VKORC1 GENETIC POLYMORPHISM IS ASSOCIATED TO VENOUS THROMBOEMBOLISM: RESULTS FROM THE EDITH STUDY
|
| Lacut K., Le Gal G., Larramendy-Gozalo C., Duchemin J., Mercier B., Gourhant L., Mottier D., Becquemont L., Oger E., Verstuyft C. |
| |
|
VKORC1: MOLECULAR TARGET OF COUMARINS
|
| Oldenburg J., Watzka M., Rost S., Müller C.R. |
| |
|
VON WILLEBRAND DISEASE TYPES 2A MUTATION (C.4789CT, P.R1597W) IN THREE IRANIAN PATIENTS
|
| Hashemi soteh M.B., Rastegar Lari G., Ala F., Jazebi M. |
| |
|
VON WILLEBRAND FACTOR (VWF) MULTIMER ANALYSIS BY IN-GEL IMMUNOSTAINING AND INFRARED IMAGING
|
| Daniels T.M., Nichols W.L., Heit J.A., Pruthi R.K., Owen W.G. |
| |
|
VON WILLEBRAND FACTOR (VWF)-BINDING TO COLLAGEN III UNDER PHYSIOLOGICAL FLOW CONDITIONS AND VWF-MEDIATED PLATELET BINDING
|
| Fuchs B., Fisseau C., Kannicht C. |
| |
|
VON WILLEBRAND FACTOR AND GPIB-IX-V REGULATE PROPLATELETS FORMATION BY HUMAN MEGAKARYOCYTES
|
| Balduini A., Pallotta I., Malara A., Lova P., Pecci A., Viarengo G., Balduini C.L., Torti M. |
| |
|
VON WILLEBRAND FACTOR BINDING PROTEIN IS A NOVEL CONFORMATIONAL ACTIVATOR OF PROTHROMBIN
|
| Kroh H.K., Panizzi P., Bock P.E. |
| |
|
VON WILLEBRAND FACTOR RELATED PARAMETERS IN SEVERE SEPSIS AND SEPTIC SHOCK
|
| Kremer Hovinga J.A., Zeerleder S., Kessler P., Romani de Wit T., van Mourik J.A., Hack C., ten Cate H., Reitsma P.H., Wuillemin W.A., Lämmle B. |
| |
|
VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE EFFECTIVELY PREVENTS EXCESSIVE BLEEDING IN PATEINTS WITH VERY LOW VWF:RCO PLASMA LEVELS
|
| Gill J.C., Leissinger C.A., DiPaola J., Bernstein J., Ragni M.V., Shopnick R., Valentino L.A., Knaub S., Friedman C. |
| |
|
VON WILLEBRAND FACTOR-GLYCOPROTEIN IB AND INTEGRIN ALPHA2BETA1-COLLAGEN INTERACTIONS MAKE COMPLEMENTARY, COLLAGEN-TYPESPECIFIC CONTRIBUTIONS TO ADHESION
|
| Jung S.M., Moroi M. |
| |
|
VULNERABLE BLOOD MEASURED BY THROMBELASTOGRAPHY: A PREDICTOR OF TARGET LESION REVASCULARIZATION AFTER CORONARY STENTING
|
| Gurbel P.A., Bliden K.P., Tantry U.S. |
| |
|
VWF A2 DOMAIN SEQUENCE 1533-1553: ITS ROLE IN CONTROLLING ADAMTS13 ACCESS TO THE Y1605-M1606 SCISSILE BOND
|
| Zanardelli S., Chion C.K.N.K., Crawley J.T.B., Moss R., Lane D.A., Chion A. |
| |
|
VWF FUNCTIONS, ADAMTS-13 ACTIVITY AND ANTIGEN LEVELS IN PATIENTS WITH LIVER CIRRHOSIS
|
| Tornai I., Papp M., Udvardy M.L., Harsfalvi J. |
| |
|
VWF INHIBITS OF THE ENDOCYTOSIS OF FACTOR VIII BY MURINE BONE MARROW-DERIVED DENDRITIC CELLS
|
| Delignat S., Dasgupta S., Navarrete A., Kaveri S.V., Lacroix-Desmazes S. |
| |
|
VWF:RCO ASSAYS USING AUTOMATED SYSTEMS FOR VWF/FVIII CONCENTRATES REQUIRE ADJUSTMENT OF ASSAY REAGENTS, COMPOSITION AND PERFORMANCE PARAMETERS
|
| Stadler M., Janisch S., Schluga P., Pock K., Gruber G., Weinberger J., Roemisch J., Svae T. |
| |
|
VWF-CLEAVING SERINE PROTEASES ISOLATION DIFFERENT FROM ADAMTS13
|
| Kempfer A., Farias C., Powazniak Y., Woods A., Calderazzo J., Keller L., Lazzari M. |
| |
